Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.
By M. Broder, D. Beenhouwer, J. Strosberg, M. Neary, D. Cherepanov. World Journal of Gastroenterology, 2015
616 citations recorded by the source corpus.
AIM To review literature on efficacy and safety of octreotide-long-acting repeatable (LAR) used at doses higher than the Food and Drug Administration (FDA)-approved 30 mg/mo for treatment of neuroendocrine tumors (NETs). METHODS We searched PubMed and Cochrane Library from 1998-2012, 5 conferences (American Society of Clinical Oncology, Endocrine Society, European Neuroendocrine Tumor Society, European Society for Medical Oncology, North American Neuroendocrine Tumor Society) from 2000-2013 using MeSH and keyterms including neuroendocrine tumors, carcinoid tumor, carcinoma, neuroendocrine, and octreotide. Bibliographies of accepted articles were also searched. Two reviewers reviewed titles, abstracts, and full-length articles. Studies that reported data on efficacy and safety of ≥ 30 mg/mo octreotide-LAR for NETs in human subjects, published in any language were included in the review. RESULTS The search identified 1086 publications, of which 238 underwent full-text review (20 were translated into English); 17 were included in the review. Studies varied in designs, subjects, octreotide-LAR regimens, and definition of outcomes. Eleven studies reported use of higher doses to control symptoms and tumor progression, although symptom severity and formal quality-of-life analysis were not quantitatively measured. Ten studies reported efficacy, describing 260 subjects with doses ranging from 40 mg/mo or 30 mg/3 wk up to 120 mg/mo. Eight studies reported expert clinical opinion that supported dose escalation of octreotide-LAR up to 60 mg/mo for symptom control and suggested increased doses may be effective at preventing tumor progression. Eight studies reported safety; there was no evidence of increased toxicity associated with doses of octreotide-LAR > 30 mg/mo. CONCLUSION As reported in this review, octreotide-LAR at doses > 30 mg/mo is being prescribed for symptom and tumor control in NET patients. Furthermore, expert clinical opinion provided support for escalation of somatostatin analogs for refractory hormonal symptoms.
Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Oncology
View Paper: https://www.semanticscholar.org/paper/557ac0f504883690c62678dc9bc4af328f689adc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Mark Houston
- Robert W. Palmatier
- John Hulland
- D. Janssen
- M. R. Larsen
- Jaroslav Vrchota
- Rune Müller Kristensen
- Kasper Pihl Kornbeck
Citations in the corpus
- Dropout Phenomena at Universities: What is Dropout? Why does Dropout Occur? What Can be Done by the Universities to Prevent or Reduce it? (2013, methodology): “The principles applied in meta-analysis are well described in the literature (e.g. Borenstein, Hedges, Higgins, & Rothstein, 2009; Torgerson, 2003).”
- Review articles: purpose, process, and structure (2018, background): “In contrast, a systematic literature review aims to Bcomprehensively locate and synthesize research that bears on a particular question, using organized, transparent, and replicable procedures at each step in the process^ (Littell et al. 2008, p. 1).”
- Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis. (2016, methodology): “Articles with a predefined quality score of ≥ 15 points, which equals 75% of the maximum 20 poin ts (12), were accepted for inclusion”
- Access to modern energy: a review of barriers, drivers and impacts (2016, methodology): “Randomized Controlled Trials (RCT), originally used in medical and epidemiological studies, have become an important methodology in development microeconomics over the last decade (Banerjee and Duflo, 2011).”
- Predictive Maintenance and Intelligent Sensors in Smart Factory: Review (2021, methodology): “The four parts of this methodology (Problem/context, Intervention, Comparison, Outcomes) create the PICO logic grid [44].”
- Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2020, neutral): “) q4w] by shortening the injection interval to 3 or even 2 weeks of long-acting SSAs to alleviate symptoms [48] although sufficient prospective data are lacking to support this approach [IV, C].”